📊 ACRS Key Takeaways
Is Aclaris Therapeutics, Inc. (ACRS) a Good Investment?
Aclaris is a clinical-stage pharmaceutical company with severe fundamental deterioration, evidenced by a 58.2% revenue collapse, massive operating losses of -$76.4M, and negative free cash flow of -$47.2M. Despite maintaining adequate liquidity and manageable debt levels, the company is burning cash at an unsustainable rate with no clear path to profitability, making it a high-risk investment for fundamentals-focused investors.
Aclaris Therapeutics shows very weak fundamentals, with revenue down 58.2% year over year and extremely negative operating and net margins, indicating the business is far from self-sustaining. While the balance sheet is not heavily levered and liquidity ratios look solid on paper, the combination of heavy operating losses and roughly $47M of annual free cash outflow versus only about $20M of cash creates substantial funding risk and weak growth quality.
Why Buy Aclaris Therapeutics, Inc. Stock? ACRS Key Strengths
- Strong liquidity position with current ratio of 3.36x and $20.0M cash reserves
- Conservative leverage with debt-to-equity of only 0.10x, reducing financial distress risk
- Positive gross margin of 41.4% indicates product viability when revenue is generated
- Low financial leverage with debt-to-equity of 0.10x and limited long-term debt
- Positive gross profit and a 41.4% gross margin indicate some residual economic value in revenue streams
- Current and quick ratios of 3.36x suggest near-term liabilities are manageable
ACRS Stock Risks: Aclaris Therapeutics, Inc. Investment Risks
- Catastrophic 58.2% year-over-year revenue decline suggests loss of major contracts or failed clinical programs
- Operating losses of $76.4M with negative FCF of $47.2M indicates unsustainable cash burn at current trajectory
- Severely negative profitability ratios (operating margin -975.9%, net margin -829.6%) demonstrate fundamental unprofitability with no near-term improvement visible
- R&D-heavy business model typical of biotech requires continued capital infusion with uncertain outcomes
- Revenue contraction of 58.2% YoY suggests weak commercial traction or unstable revenue sources
- Operating margin of -975.9% and net margin of -829.6% reflect an unsustainably unprofitable cost structure
- Negative free cash flow of $47.22M against $19.96M of cash implies likely external financing needs if burn is not reduced
Key Metrics to Watch
- Quarterly revenue trends and pipeline advancement to confirm stabilization vs. further decline
- Monthly cash burn rate and cash runway to assess solvency timeline
- Clinical trial progress and regulatory milestones for lead candidates to evaluate future revenue potential
- Quarterly cash burn relative to cash and equivalents
- Revenue stabilization and operating loss reduction
Aclaris Therapeutics, Inc. (ACRS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.36x current ratio provides a solid financial cushion.
ACRS Profit Margin, ROE & Profitability Analysis
ACRS vs Healthcare Sector: How Aclaris Therapeutics, Inc. Compares
How Aclaris Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Aclaris Therapeutics, Inc. Stock Overvalued? ACRS Valuation Analysis 2026
Based on fundamental analysis, Aclaris Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Aclaris Therapeutics, Inc. Balance Sheet: ACRS Debt, Cash & Liquidity
ACRS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Aclaris Therapeutics, Inc.'s revenue has grown significantly by 177% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.71 indicates the company is currently unprofitable.
ACRS Revenue Growth, EPS Growth & YoY Performance
ACRS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $3.3M | -$7.6M | $-0.11 |
| Q2 2025 | $1.8M | -$11.0M | $-0.13 |
| Q1 2025 | $1.5M | -$15.1M | $-0.12 |
| Q3 2024 | $4.3M | -$7.6M | $-0.11 |
| Q2 2024 | $1.9M | -$11.0M | $-0.15 |
| Q1 2024 | $2.4M | -$16.9M | $-0.24 |
| Q3 2023 | $9.3M | -$18.8M | $-0.30 |
| Q2 2023 | $1.5M | -$18.8M | $-0.31 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Aclaris Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
ACRS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Aclaris Therapeutics, Inc. (CIK: 0001557746)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ACRS
What is the AI rating for ACRS?
Aclaris Therapeutics, Inc. (ACRS) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 91% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ACRS's key strengths?
Claude: Strong liquidity position with current ratio of 3.36x and $20.0M cash reserves. Conservative leverage with debt-to-equity of only 0.10x, reducing financial distress risk. ChatGPT: Low financial leverage with debt-to-equity of 0.10x and limited long-term debt. Positive gross profit and a 41.4% gross margin indicate some residual economic value in revenue streams.
What are the risks of investing in ACRS?
Claude: Catastrophic 58.2% year-over-year revenue decline suggests loss of major contracts or failed clinical programs. Operating losses of $76.4M with negative FCF of $47.2M indicates unsustainable cash burn at current trajectory. ChatGPT: Revenue contraction of 58.2% YoY suggests weak commercial traction or unstable revenue sources. Operating margin of -975.9% and net margin of -829.6% reflect an unsustainably unprofitable cost structure.
What is ACRS's revenue and growth?
Aclaris Therapeutics, Inc. reported revenue of $7.8M.
Does ACRS pay dividends?
Aclaris Therapeutics, Inc. does not currently pay dividends.
Where can I find ACRS SEC filings?
Official SEC filings for Aclaris Therapeutics, Inc. (CIK: 0001557746) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ACRS's EPS?
Aclaris Therapeutics, Inc. has a diluted EPS of $-0.53.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ACRS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Aclaris Therapeutics, Inc. has a STRONG SELL rating with 91% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ACRS stock overvalued or undervalued?
Valuation metrics for ACRS: ROE of -63.0% (sector avg: 15%), net margin of -829.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ACRS stock in 2026?
Our dual AI analysis gives Aclaris Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ACRS's free cash flow?
Aclaris Therapeutics, Inc.'s operating cash flow is $-47.1M, with capital expenditures of $111.0K. FCF margin is -603.4%.
How does ACRS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -829.6% (avg: 12%), ROE -63.0% (avg: 15%), current ratio 3.36 (avg: 2).